Correction: miR-1323 promotes cell migration in lung adenocarcinoma by targeting Cbl-b and is an early prognostic biomarker - Scorecard - MDSpire

Correction: miR-1323 promotes cell migration in lung adenocarcinoma by targeting Cbl-b and is an early prognostic biomarker

  • By

  • Huan Zhao

  • Chunlei Zheng

  • Yizhe Wang

  • Kezuo Hou

  • Xianghong Yang

  • Yang Cheng

  • Xiaofang Che

  • Shilin Xie

  • Shuo Wang

  • Tieqiong Zhang

  • Jian Kang

  • Yunpeng Liu

  • Dianzhu Pan

  • Xiujuan Qu

  • Xuejun Hu

  • Yibo Fan

  • July 3, 2026

  • 0 min

Share

Clinical Scorecard: Correction: The Role of miR-1323 in Enhancing Cell Migration in Lung Adenocarcinoma Through Cbl-b Targeting and Its Potential as an Early Prognostic Indicator

At a Glance

CategoryDetail
ConditionLung Adenocarcinoma
Key MechanismsmiR-1323 promotes cell migration by targeting Cbl-b.
Target PopulationPatients with lung adenocarcinoma.
Care SettingOncology research and clinical settings.

Key Highlights

  • miR-1323 enhances cell migration in lung adenocarcinoma.
  • Cbl-b is identified as a target of miR-1323.
  • miR-1323 has potential as an early prognostic biomarker.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients diagnosed with lung adenocarcinoma.

          Focus on the role of miR-1323 in cell migration.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: miR-1323 promotes cell migration in lung adenocarcinoma by targeting Cbl-b and is an early prognostic biomarker

            • by Huan Zhao, Chunlei Zheng, Yizhe Wang, Kezuo Hou, Xianghong Yang, Yang Cheng, Xiaofang Che, Shilin Xie, Shuo Wang, Tieqiong Zhang, Jian Kang, Yunpeng Liu, Dianzhu Pan, Xiujuan Qu, Xuejun Hu, Yibo Fan

            • July 3, 2026

            Related Content

            Correction: Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies – a comprehensive review

            Dose rounding of trastuzumab deruxtecan in chinese patients: cost savings and safety outcomes in real-world study

            Therapeutic inhibition of RAS in non-small cell lung cancer